TSE:IVQ

Invesque Competitors

C$3.91
-0.05 (-1.26 %)
(As of 04/9/2021 03:59 PM ET)
Add
Compare
Today's Range
C$3.62
Now: C$3.91
C$4.05
50-Day Range
C$2.80
MA: C$3.27
C$4.00
52-Week Range
C$1.92
Now: C$3.91
C$4.70
Volume81,795 shs
Average Volume30,025 shs
Market CapitalizationC$218.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Invesque (TSE:IVQ) Vs. EXE, GUD, HLS, APS, BU, and VMD

Should you be buying IVQ stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Invesque, including Extendicare (EXE), Knight Therapeutics (GUD), HLS Therapeutics (HLS), Aptose Biosciences (APS), Burcon NutraScience (BU), and Viemed Healthcare (VMD).

Extendicare (TSE:EXE) and Invesque (TSE:IVQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Profitability

This table compares Extendicare and Invesque's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ExtendicareN/AN/AN/A
InvesqueN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Extendicare and Invesque, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Extendicare06102.14
Invesque01002.00

Extendicare presently has a consensus price target of C$6.63, indicating a potential downside of 15.39%. Invesque has a consensus price target of C$2.50, indicating a potential downside of 36.06%. Given Extendicare's stronger consensus rating and higher probable upside, analysts clearly believe Extendicare is more favorable than Invesque.

Valuation and Earnings

This table compares Extendicare and Invesque's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ExtendicareC$1.16 billion0.61C$53.63 millionC$0.6013.07
InvesqueC$207.96 million1.05C$-184,617,608.00C($3.30)-1.18

Extendicare has higher revenue and earnings than Invesque. Invesque is trading at a lower price-to-earnings ratio than Extendicare, indicating that it is currently the more affordable of the two stocks.

Summary

Extendicare beats Invesque on 7 of the 8 factors compared between the two stocks.

Knight Therapeutics (TSE:GUD) and Invesque (TSE:IVQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Earnings and Valuation

This table compares Knight Therapeutics and Invesque's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$199.52 million3.43C$41.08 millionC$0.3216.68
InvesqueC$207.96 million1.05C$-184,617,608.00C($3.30)-1.18

Knight Therapeutics has higher earnings, but lower revenue than Invesque. Invesque is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Knight Therapeutics and Invesque, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Knight Therapeutics00303.00
Invesque01002.00

Knight Therapeutics presently has a consensus target price of C$7.42, suggesting a potential upside of 39.41%. Invesque has a consensus target price of C$2.50, suggesting a potential downside of 36.06%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Invesque.

Profitability

This table compares Knight Therapeutics and Invesque's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Knight TherapeuticsN/AN/AN/A
InvesqueN/AN/AN/A

Summary

Knight Therapeutics beats Invesque on 7 of the 8 factors compared between the two stocks.

Invesque (TSE:IVQ) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares Invesque and HLS Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InvesqueC$207.96 million1.05C$-184,617,608.00C($3.30)-1.18
HLS TherapeuticsC$56.11 million10.89C$-15,370,026.00C($0.48)-39.75

HLS Therapeutics has lower revenue, but higher earnings than Invesque. HLS Therapeutics is trading at a lower price-to-earnings ratio than Invesque, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Invesque and HLS Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invesque01002.00
HLS Therapeutics00213.33

Invesque presently has a consensus price target of C$2.50, suggesting a potential downside of 36.06%. HLS Therapeutics has a consensus price target of C$30.50, suggesting a potential upside of 58.85%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Invesque.

Profitability

This table compares Invesque and HLS Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InvesqueN/AN/AN/A
HLS TherapeuticsN/AN/AN/A

Summary

HLS Therapeutics beats Invesque on 7 of the 9 factors compared between the two stocks.

Invesque (TSE:IVQ) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares Invesque and Aptose Biosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InvesqueC$207.96 million1.05C$-184,617,608.00C($3.30)-1.18
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79

Aptose Biosciences has lower revenue, but higher earnings than Invesque. Aptose Biosciences is trading at a lower price-to-earnings ratio than Invesque, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Invesque and Aptose Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invesque01002.00
Aptose Biosciences00203.00

Invesque presently has a consensus price target of C$2.50, suggesting a potential downside of 36.06%. Aptose Biosciences has a consensus price target of C$12.00, suggesting a potential upside of 81.54%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Invesque.

Profitability

This table compares Invesque and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InvesqueN/AN/AN/A
Aptose BiosciencesN/AN/AN/A

Summary

Aptose Biosciences beats Invesque on 4 of the 6 factors compared between the two stocks.

Invesque (TSE:IVQ) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares Invesque and Burcon NutraScience's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InvesqueC$207.96 million1.05C$-184,617,608.00C($3.30)-1.18
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00

Burcon NutraScience has lower revenue, but higher earnings than Invesque. Invesque is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Invesque and Burcon NutraScience, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invesque01002.00
Burcon NutraScience00103.00

Invesque presently has a consensus price target of C$2.50, suggesting a potential downside of 36.06%. Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Given Burcon NutraScience's stronger consensus rating and higher probable upside, analysts clearly believe Burcon NutraScience is more favorable than Invesque.

Profitability

This table compares Invesque and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InvesqueN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Summary

Burcon NutraScience beats Invesque on 7 of the 8 factors compared between the two stocks.

Invesque (TSE:IVQ) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Profitability

This table compares Invesque and Viemed Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InvesqueN/AN/AN/A
Viemed HealthcareN/AN/AN/A

Valuation & Earnings

This table compares Invesque and Viemed Healthcare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InvesqueC$207.96 million1.05C$-184,617,608.00C($3.30)-1.18
Viemed HealthcareC$131.31 million3.87C$30.86 millionC$0.7816.49

Viemed Healthcare has lower revenue, but higher earnings than Invesque. Invesque is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Invesque and Viemed Healthcare, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invesque01002.00
Viemed Healthcare01002.00

Invesque presently has a consensus price target of C$2.50, suggesting a potential downside of 36.06%. Given Invesque's higher probable upside, equities research analysts clearly believe Invesque is more favorable than Viemed Healthcare.

Summary

Viemed Healthcare beats Invesque on 4 of the 6 factors compared between the two stocks.


Invesque Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Extendicare logo
EXE
Extendicare
1.2$7.83-0.6%C$701.09 millionC$1.16 billion13.07
Knight Therapeutics logo
GUD
Knight Therapeutics
1.7$5.32-0.0%C$685.02 millionC$199.52 million16.68
HLS Therapeutics logo
HLS
HLS Therapeutics
1.4$19.20-4.2%C$610.98 millionC$56.11 million-39.75Gap Down
APS
Aptose Biosciences
1.3$6.61-1.7%C$587.53 millionN/A-9.79
BU
Burcon NutraScience
1.2$5.42-0.9%C$580.49 millionC$12,045.005,420.00News Coverage
VMD
Viemed Healthcare
0.3$12.86-0.2%C$508.77 millionC$131.31 million16.49News Coverage
Theratechnologies logo
TH
Theratechnologies
0.7$4.77-0.8%C$447.62 millionC$66.05 million-16.22Upcoming Earnings
News Coverage
BLU
BELLUS Health
0.5$5.45-1.5%C$426.94 millionC$15,000.00-10.13Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.95-0.6%C$409.34 millionC$76.09 million-58.64News Coverage
CRH Medical logo
CRH
CRH Medical
0.7$4.98-0.4%C$356.67 millionC$106.17 million-14.56
RIV
RIV Capital
0.8$2.42-6.2%C$338.68 millionC$15.44 million-3.19News Coverage
Gap Up
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22News Coverage
FIRE
The Supreme Cannabis
1.0$0.40-2.5%C$293.88 millionC$49.44 million-1.91High Trading Volume
News Coverage
Gap Up
NEPT
Neptune Wellness Solutions
1.2$1.77-4.0%C$292.92 millionC$52.78 million-1.31Gap Up
AKU
Akumin
0.7$4.08-2.0%C$282.40 millionC$246.08 million-14.02Analyst Revision
Gap Down
MDNA
Medicenna Therapeutics
0.5$5.08-0.8%C$268.74 millionN/A-16.44
ONC
Oncolytics Biotech
1.0$4.99-16.2%C$259.90 millionN/A-8.91News Coverage
Gap Down
TMD
Titan Medical
0.8$2.27-7.0%C$248.62 millionC$20 million-6.29Gap Down
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.62-0.6%C$245.11 millionC$3,000.00-6.26
Medical Facilities logo
DR
Medical Facilities
1.4$7.55-1.7%C$234.85 millionC$363.85 million26.96
ICC
ICC Labs
0.5$1.62-6.2%C$228.24 millionC$533,684.0095.29Gap Down
ATE
Antibe Therapeutics
1.3$4.88-1.0%C$222.07 millionC$9.33 million-6.20Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.82-6.5%C$203.34 millionC$170,000.00-10.24
RVX
Resverlogix
0.7$0.86-0.0%C$202.07 millionN/A78.18Upcoming Earnings
The Green Organic Dutchman logo
TGOD
The Green Organic Dutchman
0.8$0.34-2.9%C$179.25 millionC$21.50 million-0.69Gap Down
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.42-2.1%C$175.04 millionC$10,000.00-3.43Gap Up
Hamilton Thorne logo
HTL
Hamilton Thorne
1.2$1.76-1.1%C$165.83 millionC$38.36 million251.43Analyst Report
Analyst Revision
News Coverage
EPI
ESSA Pharma
0.6$8.20-6.7%C$145.78 millionN/A-8.27
LABS
MediPharm Labs
1.3$0.52-9.6%C$134.13 millionC$36.01 million-1.08Gap Up
EDT
Spectral Medical
0.5$0.55-1.8%C$131.38 millionC$2.10 million-14.10Gap Up
HBP
Helix BioPharma
0.5$0.92-1.1%C$129.84 millionN/A-16.73
IPA
ImmunoPrecise Antibodies
0.4$15.41-4.9%C$123.03 millionC$17.18 million-72.01News Coverage
Gap Up
KSI
kneat.com
1.0$3.03-0.3%C$109.53 millionC$7.42 million-35.23
Trilogy International Partners logo
TRL
Trilogy International Partners
1.1$1.83-0.5%C$108.20 millionC$610.30 million-2.20Gap Up
WMD
WeedMD
1.3$0.33-4.6%C$95.35 millionC$27.21 million-3.69News Coverage
Gap Down
Protech Home Medical logo
PTQ
Protech Home Medical
1.2$2.30-0.9%C$94.56 millionC$82.22 million-60.53
NINE
Delta 9 Cannabis
0.8$1.03-2.9%C$89.36 millionC$12.87 million19.07News Coverage
Gap Down
ACST
Acasti Pharma Inc. (ACST.V)
0.7$0.68-1.5%C$88.79 millionC$81,000.0025.19Gap Down
LXG
LexaGene
0.5$0.75-1.3%C$83.27 millionN/A-7.89
CENTRIC HEALTH logo
CHH
CENTRIC HEALTH
0.6N/AN/AC$82.18 millionC$125.52 million-2.88Gap Up
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05-0.0%C$76.88 millionC$1.09 million-1.67
FLWR
The Flowr
1.0$0.33-2.2%C$70.01 millionC$5.96 million-0.83Gap Down
KHRN
Khiron Life Sciences
0.9$0.57-1.8%C$67.34 millionC$8.01 million-2.17
PMN
ProMIS Neurosciences
0.5$0.22-0.0%C$67.31 millionC$1,787.00-11.00
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
RX
BioSyent
0.8$7.55-0.4%C$64.81 millionC$22.33 million26.03
DN
Delta 9 Cannabis
1.4$0.59-0.0%C$60.20 millionC$52.05 million-8.19News Coverage
Gap Down
MBX
Microbix Biosystems
0.9$0.55-3.6%C$60.20 millionC$11.64 million-10.78News Coverage
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.